Concurrent anti-amyloid therapy and exercise for the treatment of alzheimer's disease

Active Grant Awarded

Award ID
R03AG092563
Recipient
Awarding agency
Obligated
$301,575

Award facts

Assistance listing
93.866 Aging Research
Completion date 13% complete
Place of performance
Palo Alto, CA 94304, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded Palo Alto Veterans Institute For Research (doing business as Pavir) $301,575 on August 14, 2026, under the Aging Research program (CFDA 93.866) as Grant R03AG092563. The award funds a study testing whether combining the anti-amyloid medication lecanemab with exercise training improves outcomes in Alzheimer's disease, using the 3xTg-AD mouse line. Aim 1 tests whether the regimen reduces AD pathology and facilitates neural communication. Aim 2 tests whether it decreases cognitive loss. The work is designed to show the direct brain biochemical response to lecanemab and exercise in a controlled experimental setting, with results intended to support translation into clinical care recommendations.

The full amount is obligated at $301,575. The period of performance runs from August 14, 2026, to an ultimate completion date of August 31, 2028. Place of performance is Palo Alto, CA 94304.

The Aging Research program supports biomedical, social, and behavioral research and training, with a particular emphasis on preventing and treating Alzheimer's disease and related dementias.

Description

Abstract
Alzheimer's disease (ad) affects nearly 7 million individuals in the united states, with limited effective treatment options. Anti-amyloid therapies have shown promise but often fail to improve cognition despite addressing pathology. Ad involves inflammation and deficits in neural communication alongside plaque accumulation, necessitating treatments that extend beyond plaque removal for maximum efficacy. Exercise has shown promise in enhancing neural communication and reducing inflammation through many mechanisms, including increasing brain-derived neural trophic factor (BDNF) and regulating microglia. Combining exercise with the anti-amyloid medication lecanemab could improve the quality of life for patients with ad by addressing multiple dimensions of ad pathology. The study thus aims to test the effectiveness of combining lecanemab with exercise training for ad using the 3XTG-ad mouse line. We hypothesize that this treatment regimen will reduce ad pathology and facilitate neural communication (aim 1); and decrease cognitive loss (aim 2). This innovative project addresses the multidimensional components of neurodegeneration and has the potential for expansion to more complex research projects. Results will uniquely shed light on the direct brain biochemical response to lecanemab and exercise in a controlled experimental setting, facilitating translation into clinical care recommendations.

Quick answers

Who received award R03AG092563?

R03AG092563 was awarded to Palo Alto Veterans Institute For Research by National Institute on Aging (National Institutes of Health) on August 14, 2026.

How much is award R03AG092563 worth?

$301,575 has been obligated on R03AG092563.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award